%0 Journal Article
%A El-Battrawy, Ibrahim
%A Nuñez-Gil, Ivan J
%A Abumayyaleh, Mohammad
%A Estrada, Vicente
%A Manuel Becerra-Muñoz, Víctor
%A Uribarri, Aitor
%A Fernández-Rozas, Inmaculada
%A Feltes, Gisela
%A Arroyo-Espliguero, Ramón
%A Trabattoni, Daniela
%A López-País, Javier
%A Pepe, Martino
%A Romero, Rodolfo
%A Castro-Mejía, Alex F
%A Cerrato, Enrico
%A Capel Astrua, Thamar
%A D'Ascenzo, Fabrizio
%A Fabregat-Andres, Oscar
%A Signes-Costa, Jaime
%A Marín, Francisco
%A Buonsenso, Danilo
%A Bardají, Alfredo
%A Jesús Tellez, María
%A Fernández-Ortiz, Antonio
%A Macaya, Carlos
%A Akin, Ibrahim
%T COVID-19 and the impact of arterial hypertension-An analysis of the international HOPE COVID-19 Registry (Italy-Spain-Germany).
%D 2021
%U http://hdl.handle.net/10668/18392
%X A systematic analysis of concomitant arterial hypertension in COVID-19 patients and the impact of angiotensin-converting-enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs) have not been studied in a large multicentre cohort yet. We conducted a subanalysis from the international HOPE Registry (https://hopeprojectmd.com, NCT04334291) comparing COVID-19 in presence and absence of arterial hypertension. Out of 5837 COVID-19 patients, 2850 (48.8%) patients had the diagnosis arterial hypertension. 1978/2813 (70.3%) patients were already treated with ACEI or ARBs. The clinical outcome of the present subanalysis included all-cause mortality over 40 days of follow-up. Patients with arterial hypertension suffered significantly more from different complications including respiratory insufficiency (60.8% vs 39.5%), heart failure (9.9% vs 3.1%), acute kidney injury (25.3% vs 7.3%), pneumonia (90.6% vs 86%), sepsis (14.7% vs 7.5%), and bleeding events (3.6% vs 1.6%). The mortality rate was 29.6% in patients with concomitant arterial hypertension and 11.3% without arterial hypertension (P  The mortality rate and in-hospital complications might be increased in COVID-19 patients with a concomitant history of arterial hypertension. The history of ACEI or ARBs treatments does not seem to impact the outcome of these patients.
%K COVID
%K hypertension
%~